Physician profile
Krista Murphy
NPI 1700231057
$15,742.41
in general payments reported to CMS, 2019-2025
24 companies · $2,893 in 2025
The $2,893 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $835 · 2022: $2,068 · 2023: $4,595 · 2024: $5,351 · 2025: $2,893.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,298 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $4,300 · Education: $242.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,297.53 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $4,300.00 |
| Education | $241.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,731.57 | 2021-2025 | |
| Vanda Pharmaceuticals INC. | $1,309.98 | 2022-2025 | Fanapt, Hetlioz |
| Otsuka America Pharmaceutical, INC. | $1,242.42 | 2021-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Teva Pharmaceuticals USA, INC. | $1,226.29 | 2021-2025 | Austedo Xr, Uzedy, Austedo Xr |
| Alkermes, INC. | $1,150.27 | 2022-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,075.67 | 2022-2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $741.69 | 2022-2025 | Spravato, Invega Sustenna, Invega |
| Supernus Pharmaceuticals, INC. | $504.03 | 2021-2023 | Qelbree |
| Lundbeck LLC | $464.30 | 2021-2025 | Rexulti |
| E.R. Squibb & Sons, L.L.C. | $434.32 | 2024-2025 | Cobenfy |
| Axsome Therapeutics, INC. | $383.42 | 2023-2025 | Auvelity |
| Neurocrine Biosciences, INC. | $341.79 | 2021-2025 | Ingrezza |
| Eisai INC. | $263.70 | 2021-2022 | |
| Corium, LLC | $256.35 | 2022-2024 | Azstarys |
| Merck Sharp & Dohme LLC | $138.99 | 2022-2023 | Belsomra |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almatica Pharma LLC | $137.38 | 2022-2024 | Loreev Xr, Sertraline Hcl |
| Takeda Pharmaceuticals U.S.A., INC. | $130.11 | 2021-2024 | Trintellix |
| Neos Therapeutics, LP | $55.45 | 2021-2024 | Adzenys Xr-Odt |
| Ironshore Pharmaceuticals INC. | $33.44 | 2023 | Jornay Pm |
| Avanir Pharmaceuticals, INC. | $30.99 | 2022 | |
| Sunovion Pharmaceuticals INC. | $28.58 | 2021 | |
| Jazz Pharmaceuticals INC. | $24.78 | 2022 | |
| Tris Pharma INC | $18.95 | 2022 | |
| Collegium Pharmaceutical, INC. | $17.94 | 2025 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Krista Murphy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.